http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112263578-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112263578-B |
| titleOfInvention | Application of Tipranavir in preparation of cancer treatment medicine for killing tumor stem cells and tumor cells |
| abstract | The invention discloses application of Tipranavir in preparation of a cancer treatment drug for killing tumor stem cells and tumor cells, and relates to the technical field of medicines. The invention also discloses a cancer treatment drug, which can kill tumor stem cells and tumor cells; the medicament takes Tipranavir as a main active ingredient and contains a pharmaceutically acceptable carrier. The invention provides the first time that Tipranavir can be used for preparing an anticancer drug for killing tumor stem cells and tumor cells, the anti-gastric cancer effect of the Tipranavir is obviously superior to that of the existing first-line therapeutic drugs for gastric cancer (5-FU and cissplatin are combined), the Tipranavir has no obvious toxic or side effect, the toxic or side effect is obviously smaller than that of the first-line therapeutic drugs for gastric cancer (5-FU and cissplatin are combined), a new drug and a new scheme are provided for tumor treatment of targeted tumor stem cells and tumor healing thereof, and the Tipranavir has important significance for improving the tumor treatment effect and the life quality of patients. |
| priorityDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.